Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTUNG.L Regulatory News (TUNG)

  • There is currently no data for TUNG

Market update

25 Sep 2014 07:27

RNS Number : 5777S
Tungsten Corporation PLC
25 September 2014
 

TUNGSTEN CORPORATION PLC 

 

("Tungsten" or the "Company")

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN NOR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

 

 

For Immediate Release 25 September 2014

 

 

Market update

Pharmaceutical and healthcare companies continue to choose Tungsten Network

Seven of the top-twelve global pharmaceutical businesses use the global e-Invoicing network

 

London, 25 September - Tungsten Network is the e-Invoicing provider of choice for the world's leading pharmaceutical and healthcare companies.

The latest organisations to select Tungsten Network include Fresenius Medical Care NA, a US-based provider of kidney dialysis services and renal care products, and Dana-Farber Cancer Institute, a world leader in cancer treatment and research.

These new customers join the global e-Invoicing network alongside long-term practitioners, such as GlaxoSmithKline, and reinforce Tungsten's strength in this industry. Seven of the twelve largest pharmaceutical companies in the world, ranked by revenue, transact with their suppliers through Tungsten Network.

"The pharmaceutical sector has been an early adopter of e-Invoicing with our first customer from the industry joining the network in 2004," says Edmund Truell, Tungsten Group CEO. "It's befitting that an industry focused on innovation is equally pioneering in its own business practices."

 

Enquiries:

 

Tungsten Corporation plc

Edmund Truell, Chief Executive Officer +44 20 3435 5680

 

Charles Stanley Securities

(Nominated Adviser and Joint Broker)

Marc Milmo/Dugald Carlean +44 20 7149 6000

 

Canaccord Genuity Limited

(Joint Broker)

Simon Bridges/Peter Stewart/Cameron Duncan +44 20 7523 8000

 

Equus Group (Communications)

Piers Hooper / Sam Barton +44 20 7223 1100

 

About Tungsten Corporation plcTungsten Corporation (LSE: TUNG) accelerates global trade by enabling customers to streamline invoice processing, improve cash-flow management and make better buying decisions from their detailed spend data.

 

Buyer organisations that join Tungsten Network, built on OB10 e-Invoicing, can reduce their invoice-processing costs by 60%. Suppliers benefit from efficiencies, greater visibility of their invoice status and peace of mind. Tungsten offers supply chain financing through Tungsten Bank and helps buying organisations profit by applying real-time spend analytics to its vast repository of line-level invoice data.

 

Tungsten serves 53% of the Fortune 500 and 66% of the FTSE 100 by connecting the world's largest companies and government agencies to their thousands of suppliers around the globe. It is compliant in 46 countries, and last year processed transactions worth over $187bn for organisations such as Alliance Data, Aviva, Cargill, Deutsche Lufthansa, General Motors, GlaxoSmithKline, Henkel, IBM, Kellogg's, and US Federal Government.

 

Tungsten Corporation joined forces with OB10 in 2013 to create the world's largest electronic trading network.

 

Contact: Sandra Higgison, Head of Global Communications, +44 20 7280 7973, sandra.higgison@tungsten-network.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRALAMFTMBBTMLI
Date   Source Headline
23rd Mar 20212:15 pmRNSCustomer Loss
17th Mar 20214:35 pmRNSPrice Monitoring Extension
16th Mar 20214:40 pmRNSSecond Price Monitoring Extn
16th Mar 20214:36 pmRNSPrice Monitoring Extension
12th Feb 20217:00 amEQSTungsten (TUNG): Foundations for growth in place
19th Jan 20214:15 pmRNSHolding(s) in Company
19th Jan 20214:10 pmRNSHolding(s) in Company
15th Jan 20214:36 pmRNSPrice Monitoring Extension
6th Jan 202111:00 amRNSHolding(s) in Company
4th Jan 20217:00 amRNSHolding(s) in Company
18th Dec 20204:30 pmRNSHolding(s) in Company
14th Dec 20207:00 amRNSInterim Results
11th Dec 20207:00 amRNSNew Customer Win
10th Dec 20201:05 pmRNSHolding(s) in Company
1st Dec 20204:40 pmRNSSecond Price Monitoring Extn
1st Dec 20204:35 pmRNSPrice Monitoring Extension
27th Nov 20207:00 amRNSTrading Update
2nd Nov 20204:31 pmRNSAdditional Listing and Total Voting Rights
2nd Nov 20204:30 pmRNSDirector/PDMR Shareholding
23rd Oct 20201:05 pmRNSHolding(s) in Company
20th Oct 20207:00 amRNSAppointment of Non-Executive Director
16th Oct 20203:50 pmRNSResult of AGM
15th Oct 20205:49 pmRNSAdditional Listing and TVR
2nd Oct 20207:00 amRNSAdditional Listing and Total Voting Rights
23rd Sep 20207:00 amRNSBlock Listing Application
15th Sep 202012:30 pmRNSHolding(s) in Company
11th Sep 20207:00 amRNSDirectorate Change
9th Sep 20207:00 amRNSHolding(s) in Company
7th Sep 20207:00 amRNSFinal Results
20th Jul 20207:00 amRNSTrading Update
2nd Jul 20201:00 pmRNSHolding(s) in Company
22nd Jun 20207:00 amRNSReporting Timetable
17th Apr 20207:00 amRNSAppointment of Chief Financial Officer
3rd Apr 202012:05 pmRNSDirector/PDMR Share Dealing
2nd Apr 20202:15 pmRNSDirector/PDMR Share Dealing
31st Mar 20201:40 pmRNSAppointment of Non Executive Director
31st Mar 202012:07 pmRNSSecond Price Monitoring Extn
31st Mar 202012:02 pmRNSPrice Monitoring Extension
31st Mar 202011:16 amRNSChange of Nominated Adviser
23rd Mar 20207:00 amRNSCOVID-19 Update
19th Mar 202011:45 amRNSDirector/PDMR Share Dealing
16th Mar 20201:15 pmRNSHolding(s) in Company
10th Mar 20207:00 amRNSTrading Update for the Nine Months to 31 Jan 2020
6th Mar 202012:07 pmRNSSecond Price Monitoring Extn
6th Mar 202012:02 pmRNSPrice Monitoring Extension
5th Feb 20202:46 pmRNSDIRECTORATE CHANGE UPDATE
4th Feb 20204:40 pmRNSSecond Price Monitoring Extn
4th Feb 20204:35 pmRNSPrice Monitoring Extension
22nd Jan 20207:00 amRNSDIRECTORATE CHANGE
10th Jan 20204:15 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.